Influence of Atorvastatin on Viral Replication During Antiretroviral Treatment Interruption
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Atorvastatin, Viral replication, HIV-1, plasma cholesterol, Cell membrane cholesterol
Eligibility Criteria
Inclusion Criteria: Age >= 18 years. Patients with chronic infection by HIV-1 in stable highly active antiretroviral treatment (>= 6 months). Undetectable plasma viral load (<50 copies/mL) in the last 3 determinations over the last 6 months. CD4 > 500 cells/mm>=3 in the last two determinations. Documented prior viral load at some time of >15,000 copies/mL. Women may not be of fertile age (defined as at least one year from menopause or undergoing any surgical sterilisation technique), or must undertake to use a barrier contraceptive method during the study. Signature of the informed consent Exclusion Criteria: CD4 nadir <= 200 cells/mm3. Background of infections or other AIDS-defining pathology. Intercurrent infections in the last 6 months. Creatine kinase (CK) >= 500 U/L. AST or ALT >= 3 times higher than the upper limit of normality. Treatment with others statins, fibrates, macrolides or fluconazole in the last 3 months. Pregnancy or breastfeeding Patients participating in another clinical trial
Sites / Locations
- Germans Trias i Pujol Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
A
B
4 semanas manteniendo el tratamiento antirretroviral e iniciar atorvastatina 40 mg/día. A la semana 4 interrupción HAART y aumentar a 80 mg/día de atorvastatina hasta la semana 32 de seguimiento
4 semanas manteniendo el tratamiento antirretroviral. A la semana 4 interrupción HAART hasta la semana 32 de seguimiento